Nektar also has a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with numerous companies.
 

Products by Therapeutic Area Nektar
Discovered
Indication Phase view all Partner
       
Oncology  
Etirinotecan pegol (NKTR-102) Metastatic Breast Cancer
Phase 3
 
Etirinotecan pegol (NKTR-102) Platinum-Resistant Ovarian Cancer
Phase 2
 
Etirinotecan pegol (NKTR-102) Second-Line Colorectal Cancer
Phase 2
 
Etirinotecan pegol (NKTR-102) GI and solid tumors
In combination with
5-FU

Phase 1
 
NKTR-214 Oncology
Preclinical
 
CNS/Pain  
Naloxegol (NKTR-118) Opioid-induced constipation (OIC)
Phase 3
AstraZeneca
NKTR-119 Analgesic for pain
Preclinical
AstraZeneca
NKTR-181 Chronic pain
Phase 2
 
NKTR-192 Acute pain
Phase 1
 
NKTR-171 Neuropathic pain
Preclinical
 
Immunology /Inflammation  
Cimzia®   Crohn’s Disease (US)
Rheumatoid Arthritis

Approved US/Approved EU
UCB Pharma
Cimzia®   Psoriatic Arthritis
Ankylosing Spondylitis

Phase 3
UCB Pharma
NKTR-125 Allergic Rhinitis
Preclinical
 
Anti-Infectives  
Amikacin Inhale (NKTR-061)
(BAY41-6551)
Gram-negative pneumonia
Phase 3
Bayer
Ciprofloxacin DPI
(BAY Q3939)
Non-cystic fibrosis bronchiectasis
Phase 3
Bayer
Hemophilia  
BAX 855 (full-length longer-acting rFVIII molecule) Hemophilia A
Phase 2/3
Baxter
Longer-acting therapeutic clotting proteins Hemophilia and bleeding disorders
Preclinical
Baxter
Endocrine/Metabolic  
NKTR-228 Renal Disease
Preclinical
 
Other Royalty-Bearing Licensing Partnerships  
LEVADEX™   Migraine
Phase 3 complete - NDA filed
MAP Pharmaceuticals
OMONTYS®
a product under development by Takeda and Affymax
  Renal Anemia
Approved US/Filed EMA
Affymax

* LEVADEX™ is a trademark and TEMPO® is a registered trademark of MAP Pharmaceuticals; Cimzia® is a registered trademark of UCB and OMONTYS is a registered trademark of Affymax, Inc.

BAX 855 (full-length longer-acting rFVIII molecule)

  • BAX 855 is a full-length longer-acting recombinant factor VIII (rFVIII) that was developed to increase the half-life of ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] - the most widely chosen rFVIII in the world. Through a collaboration with Nektar, BAX 855 leverages our proprietary PEGylation technology designed to extend the duration of activity of proteins. The technology has been shown to be safe and tolerable and is used in various approved treatments. A Phase 1 study showed the half-life of BAX 855 was approximately 1.5-fold higher compared to ADVATE and has the potential for less frequent dosing.

  • BAX 855 is Baxter's most advanced longer-acting candidate, and is in Phase 2/3 clinical development. The Phase 2/3 multicenter, open-label study of BAX 855 called PROLONG-ATE will enroll 100 previously-treated adult patients with severe hemophilia A to assess the efficacy, safety and pharmacokinetics of BAX 855 for prophylaxis and on-demand treatment of bleeding. Information and enrollment details for the trial are available at www.clinicaltrials.gov or by emailing medinfo@baxter.com.
Longer-acting therapeutic clotting proteins

Nektar and Baxter have multiple partnerships in hemophilia. Under the terms of these collaborations, Nektar is entitled to receive royalties on the global sales of long-acting clotting protein programs for hemophilia that use Nektar's PEGylation and advanced polymer conjugate technologies. Nektar is also entitled to contract research and manufacturing revenues for these programs. Nektar's innovative releasable linker conjugate technology is used in the development of these therapeutics.
LEVADEX™

Under the terms of a license agreement between Nektar and MAP Pharmaceuticals, Nektar is entitled to receive royalties on the global sales of LEVADEX™ for all indications. LEVADEX is an orally inhaled version of dihydroergotamine (DHE), self-administered via MAP's proprietary TEMPO® inhaler. DHE is available as an intravenous therapy which has been used in clinical settings for over 50 years to safely treat migraine. A New Drug Application (NDA) for LEVADEX is currently being reviewed by the U.S. Food and Drug Administration (FDA) and the PDUFA is April 15, 2013.
Ciprofloxacin DPI

Under development by Bayer Healthcare, Ciprofloxacin Dry Powder for Inhalation (DPI) is an innovative drug-device combination being investigated in non-CF bronchiectasis (NCFB). The investigational product candidate is currently in Phase 3 clinical trials in patients with NCFB and features a small, hand-held inhaler for ease-of-use. Nektar is entitled to royalties on sales of Ciprofloxacin DPI upon commercialization.
Amikacin Inhale (NKTR-061)

  • Aerosolized antibiotic in both on and off ventilator setting

    Amikacin Inhale is a drug-device combination product, comprised of a specially formulated Amikacin Inhalation Solution with Nektar’s Pulmonary Drug Delivery System (PDDS). It is being developed in partnership with Bayer HealthCare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia. The unique areosolization system, PDDS, was designed to achieve optimal lung penetration of the specially formulated Amikacin Inhale Solution, delivering antimicrobial agent directly to the site of infection in the lungs.
  • Naloxegol (NKTR-118)

  • Internally discovered by Nektar
  • In Phase 3 Studies

    Oral Naloxegol (NKTR-118) is a novel peripheral opioid antagonist created using Nektar's advanced polymer conjugate technology.
  • Naloxegol and opioid co-formulation product

  • Invented by Nektar
  • Currently in research/preclinical

    Oral NKTR-119 is an investigational drug candidate that is a co-formulation of Oral Naloxegol (NKTR-118) and an opioid analgesic. The product is in preclinical stages for the treatment of pain without the gastrointestinal side effects associated with traditional opioid therapies.
  • NKTR-181

  • Invented by Nektar
  • Currently in Phase 2 clinical trials for chronic pain

    NKTR-181 is a new oral opioid analgesic candidate in development for the treatment of chronic pain. It is designed to address the abuse liability and serious central nervous system (CNS) side effects associated with current opioid therapies. NKTR-181 is a novel mu-opioid agonist created using Nektar's proprietary polymer conjugate technology and its differentiating properties are inherent to the design of its new molecular structure.
  • NKTR-171

  • Invented by Nektar
  • Currently in preclinical studies

    NKTR-171 is a drug candidate designed to treat neuropathic pain without the CNS side effects. The product was developed using Nektar's advanced polymer conjugate technology and is in early research.
  • NKTR-192

  • Invented by Nektar
  • Currently in Phase 1 Clinical Studies

    NKTR-192 is Nektar Therapeutics' product candidate for the treatment of moderate to severe acute pain. NKTR-192 is a novel mu-opioid analgesic created using Nektar's advanced polymer conjugation technology to slow drug entry into the central nervous system (CNS). By dramatically slowing the rate of drug entry into the CNS, NKTR-192 is intended to maintain opioid-like efficacy without the abuse potential associated with rapid-acting opioids.
  • Cimzia®

    Nektar technology is used in the antibody fragment, Cimzia® (certolizumab pegol). Cimzia is the first and only PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody approved by the FDA for Crohn's disease. This product is approved in the U.S. and filed in the EU for rheumatoid arthritis and in phase 3 for ankylosing spondylitis and psoriatic arthritis. Under the terms of the agreement between Nektar and UCB, Nektar will receive manufacturing revenues and royalties on global sales for all indications.
    NKTR-125

  • Invented by Nektar
  • Currently in preclinical studies
  • Antihistamine without CNS side effects

    Combines Nektar Advanced Polymer Conjugate Technology™ with a potent antihistamine to enhance its anti-inflammatory properties and minimize the undesirable side effects.
  • Etirinotecan pegol (NKTR-102)

  • Internally discovered by Nektar
  • Currently in Phase 3 clinical trials in metastatic breast cancer
  • Novel pro-drug topoisomerase I inhibitor

    Etirinotecan pegol is a topoisomerase I inhibitor-polymer conjugate with a unique pharmacokinetics profile that provides a continuous concentration of active drug with reduced peak concentrations. Etirinotecan pegol was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform.
  • Etirinotecan pegol (NKTR-102)

  • Internally discovered by Nektar
  • Currently in Phase 2 clinical trials in platinum-resistant ovarian      cancer
  • Novel pro-drug topoisomerase I inhibitor

    Etirinotecan pegol is a topoisomerase I inhibitor-polymer conjugate with a unique pharmacokinetics profile that provides a continuous concentration of active drug with reduced peak concentrations. Etirinotecan pegol was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform.
  • Etirinotecan pegol (NKTR-102)

  • Internally discovered by Nektar
  • Currently in Phase 2 clinical trials in second-line colorectal cancer
  • Novel pro-drug topoisomerase I inhibitor

    Etirinotecan pegol is a topoisomerase I inhibitor-polymer conjugate with a unique pharmacokinetics profile that provides a continuous concentration of active drug with reduced peak concentrations. Etirinotecan pegol was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform.
  • Etirinotecan pegol (NKTR-102)

  • Internally discovered by Nektar
  • Currently in Phase 1 clinical trials in multiple tumor settings
  • Novel pro-drug topoisomerase I inhibitor

    Etirinotecan pegol is a topoisomerase I inhibitor-polymer conjugate with a unique pharmacokinetics profile that provides a continuous concentration of active drug with reduced peak concentrations. Etirinotecan pegol was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform.
  • OMONTYS® (peginesatide)

    Nektar's proprietary conjugation technology is used in the novel peptide mimetic, OMONTYS (peginesatide) Injection. The therapeutic is a synthetic, peptide-based erythropoiesis-stimulating agent developed by Takeda and Affymax. Under the terms of an exclusive agreement between Nektar and Affymax, Nektar is entitled to receive royalties on the global sales of OMONTYS for all indications, as well as manufacturing revenues. OMONTYS is approved by the U.S. Food and Drug Administration (FDA)for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis. A Marketing Authorization Application for peginesatide is currently under review by the European Medicines Agency.
    CDP791

    Nektar technology is used in the antibody fragment, CDP791. The product is in Phase 2 clinical trials for non-small cell lung cancer. Under the terms of the agreement between Nektar and UCB, Nektar will receive manufacturing revenues and royalties on global sales of CDP791 for all indications.
    NKTR-228

  • Invented by Nektar
  • Currently in research/preclinical

    NKTR-228 is a drug candidate designed to reduce parathyroid hormone levels in late stage renal disease patients. The product was developed using Nektar's advanced polymer conjugate technology and is in early research.
  • NKTR-214

  • Invented by Nektar
  • Currently in research/preclinical

    NKTR-214 is a drug candidate designed to kill tumors through stimulation of the immune system. The product was developed using Nektar's advanced polymer conjugate technology and is in early research.
  •  
     
    Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide